Wall Street Analysts See a 258.21% Upside in Adicet Bio (ACET): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 258.2% in Adicet Bio (ACET). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?
Here is how Adicet Bio, Inc. (ACET) and Centene (CNC) have performed compared to their sector so far this year.
Here's Why You Should Add ACET Stock to Your Portfolio Now
Adicet Bio advances prula-cel in autoimmune diseases while pursuing new opportunities in prostate cancer and in vivo CAR-T.
Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
Here is how Adicet Bio, Inc. (ACET) and Agilent Technologies (A) have performed compared to their sector so far this year.
Wall Street Analysts Think Adicet Bio (ACET) Could Surge 301.57%: Read This Before Placing a Bet
The consensus price target hints at a 301.6% upside potential for Adicet Bio (ACET). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Adicet Bio Eyes Key Lupus Data This Quarter for Off-the-Shelf Cell Therapy
Adicet Bio NASDAQ: ACET expects to report clinical data this quarter for its lead autoimmune program, ADI-001, also known as prula-cel, including results in lupus nephritis (LN) and systemic lupus erythematosus (SLE), Chief Executive Officer Chen Schor said at the 46th Annual Canaccord Genuity Growth Conference.
All You Need to Know About Adicet Bio (ACET) Rating Upgrade to Buy
Adicet Bio (ACET) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Adicet Bio (ACET) Stock Outpacing Its Medical Peers This Year?
Here is how Adicet Bio, Inc. (ACET) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.
Adicet Bio Teases Autoimmune Data Catalysts, PSMA Plans at Jefferies Conference
Adicet Bio NASDAQ: ACET outlined its near-term clinical priorities and upcoming data catalysts during a fireside chat at the Jefferies Healthcare Conference in New York, with President and CEO Chen Schor emphasizing the company's focus on off-the-shelf gamma delta 1 T-cell therapies for autoimmune disease and oncology.
Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
Here is how Adicet Bio, Inc. (ACET) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.
Wall Street Analysts Believe Adicet Bio (ACET) Could Rally 319.64%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 319.6% in Adicet Bio (ACET). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Adicet Bio (ACET) Upgraded to Buy: Here's Why
Adicet Bio (ACET) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
